Rapid Dose Therapeutics Strengthens Leadership Team with Addition of Rodney Butt & Appoints New Advisory Board Member


Ryan Allway

December 15th, 2021

News


Additions to support immediate commercialization efforts for the Company’s COVID-19 vaccine candidate

 

BURLINGTON, Ontario, December 15, 2021–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company“) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is pleased to announce a significant addition to the Company’s leadership team with the appointment of Rodney Butt as the lead consultant overseeing the development of the Company’s COVID-19 vaccine delivery platform. Initial results demonstrate viability and stability of both protein-based and mRNA-based vaccine candidates when incorporated into the oral dispersible film.

 

Mr. Butt brings a wealth of expertise to RDT with more than 30 years prescription drug development experience. Mr. Butt has been involved in all aspects of pharmaceutical drug development, clinical trial design, as well as optimizing organizational design. Previously, Mr. Butt has held many important roles, including President of Adiga Life Sciences, a joint venture between McMaster University and Circassia (UK), Business Unit Manager for AAIPharma, a US based CRO and Director of Research for Boehringer Ingelheim where he managed a 50-member team actively engaged in all aspects of clinical research activities. In addition, Mr. Butt was a member of the Germany-based Clinical Expert Group responsible for managing cardiovascular drug development. Mr. Butt is a frequent speaker at pharma Industry events and is a lecturer in drug development at the University of Guelph. Mr. Butt completed his MSc in Clinical Trial Methodology at McMaster University and his MBA at Queen’s University.

 

“We are thrilled that Mr. Butt has chosen the commercialization of the RDT COVID-19 vaccine delivery candidate as the next major project that he will undertake, adding to his vast expertise bringing novel products to market,” said Mark Upsdell, CEO, Rapid Dose Therapeutics. “His extensive relationships within the pharmaceutical sector along with his expertise with clinical trial management gives us tremendous confidence that Mr. Butt is the ideal addition to our leadership team.”

 

Rapid Dose Therapeutics would also like to confirm their commitment to bringing scientifically sound and medically relevant products to the market with the appointment Dr. Richard Tytus to the Company’s Advisory Board. Dr. Tytus will be responsible for supporting RDT’s leadership with strategic counsel and will facilitate introductions to relevant partners that will enhance commercialization of the RDT COVID-19 vaccine delivery system.

 

Dr. Tytus is an Associate Clinical Professor in the Department of Family Medicine at McMaster University and co-founder of Banty, a virtual medical video platform. He has a proven track record working with innovative approaches that enhance a patient’s interaction with health care providers. Dr. Tytus is the Chair for District Four of the Ontario Medical Association (OMA) and an active member of the National Virtual Care Task Force. Previously, he served on the Board for the OMA, is Past-Chair of OntarioMD, and Past President of the Hamilton Academy of Medicine. Dr Tytus is a well-respected member of the medical community a leader in medical education.

 

“The addition of Dr. Tytus to our Advisory Board opens many doors for us with pharmaceutical companies and medical professionals, institutions and investors, all critical to the successful commercialization of our game changing COVID-19 vaccine delivery platform,” added Mr. Upsdell. “Dr. Tytus will be instrumental in helping to introduce our breakthrough technology and support the implementation of our strategic alliances needed to bring this product to fruition.”

 

In addition, the Company is announcing the granting of incentive stock options to Mr. Butt and Dr. Tytus to purchase, in total, 500,000 common shares at an exercise price of $.58 per share. The options vest equally every six months over a two-year period and expire on December 14, 2026.

 

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

 

www.rapid-dose.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005231/en/

 

Contacts

Investors:
Mark Upsdell, CEO
mupsdell@rapid-dose.com
416-477-1052

Media:
Kim Robinson
krobinson@rapid-dose.com
905-330-4055

 

 

 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading